



**From:** Doug.Fenwick [mailto:Doug.Fenwick]  
**Sent:** Thursday, September 19, 2013 7:41 PM  
**Cc:** Michael.Carland; Michelle.Richens; Robert.Spence  
**Subject:** Re: Urgent TGA inquiry - information on the [REDACTED] site [SEC=UNCLASSIFIED]  
**Importance:** High

Hi [REDACTED]

I would really appreciate an early response on this, even if partial.

Thanks

Regards

**Doug Fenwick** B. Pharm, MBA  
Head of Office (Acting)  
Office of Manufacturing Quality  
Therapeutic Goods Administration  
Department of Health and Ageing

Phone: 02 9865 9304  
Fax: 02 6203 1526  
Email: [doug.fenwick](mailto:doug.fenwick)

Therapeutic Goods Administration  
PO Box 100  
Woden ACT 2606  
[www.tga.gov.au](http://www.tga.gov.au)

*From August 2012, the Office of Manufacturing Quality is using the term 'inspect' instead of 'audit' to describe its core regulatory activities.*

From: Robert Spence/TGA/Health  
To: [REDACTED]  
Cc: Doug Fenwick/TGA/Health [REDACTED] Michael Carland/TGA/Health [REDACTED] Michelle Richens/TGA/Health [REDACTED]  
Date: 19/09/2013 10:16 AM  
Subject: Urgent TGA inquiry - information on the [REDACTED] site [SEC=UNCLASSIFIED]

Dear FDA Colleagues

I am an associate of both Doug Fenwick and Anton Norder holding the position in TGA's Office of Manufacturing Quality of Projects and Planning Officer. In that capacity, I need to follow up on the media release at [REDACTED] and [REDACTED] outlining concerns with [REDACTED]

To allow us to better understand the situation with [REDACTED] and address some of the queries we are receiving, could I ask for a response on the following points as a urgent matter:

1. We have two [REDACTED] manufacturing sites on the TGA books that reference the [REDACTED] suburb. I need to firstly confirm that the location of the site in question is [REDACTED] [REDACTED] Please confirm that this is correct site address. Of course our strategy for

dealing with the matter centres on having the correct site in the cross hairs. [REDACTED]

[REDACTED]

[REDACTED]

Please contact me immediately if any points above need clarification or additional information.

Any information provided by your agency will be retained in confidence, in accordance with the cooperation arrangements and confidentiality undertakings exchanged between the TGA and the US FDA. The material is confidential non-public information and will not be disclosed to third parties without your agency's prior written agreement.

Thank you in advance.

Rob Spence  
Projects and Planning Officer  
Office of Manufacturing Quality

Phone: 02 6232 8752

email: robert.spence [REDACTED]

Therapeutic Goods Administration  
Department of Health and Ageing  
PO Box 100  
Woden ACT 2606

[www.tga.gov.au](http://www.tga.gov.au)

[REDACTED]